Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tapinarof - Dermavant Sciences/Welichem Biotech

Drug Profile

Tapinarof - Dermavant Sciences/Welichem Biotech

Alternative Names: Benvitimod; DHPS; DMVT 505; GSK-2894512; WBI-1001

Latest Information Update: 29 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Welichem Biotech
  • Developer Beijing Wenfeng Tianji Pharmaceuticals; Celestial Pharmaceuticals; Dermavant Sciences; Stiefel Laboratories; Welichem Biotech
  • Class Antipsoriatics; Nonsteroidal anti-inflammatories; Resorcinols; Skin disorder therapies; Small molecules; Stilbenes
  • Mechanism of Action Aryl hydrocarbon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis; Psoriasis
  • Phase II Atopic dermatitis
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 14 Aug 2019 Dermavant Sciences plans a phase III trial for Plaque Psoriasis in August 2019 (Topical) (NCT04053387)
  • 13 Aug 2019 Dermavant Sciences initiates a phase III trial for Plaque Psoriasis in USA (Topical) (NCT04053387)
  • 23 Jul 2019 Dermavant Sciences initiates a phase III trial for Plaque psoriasis in USA (NCT04042103)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top